News

pharmaphorum3d
Regeneron’s cholesterol drug evinacumab claims February FDA date
The FDA has started a speedy review ... in the risk of developing heart disease, If approved, it will sit alongside Sanofi-partnered PCSK9 inhibitor Praluent (alirocumab) – which has ...
Hosted on MSN1mon
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AstraZeneca AZN announced that the FDA has approved its blockbuster drug ... stage study of its investigational once-daily oral PCSK9 inhibitor, AZD0780, at the annual session of the American ...
LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight
DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...
Morningstar1mon
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
A drug that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and rolling review of any application for marketing approval. A drug ...
Yahoo Finance5d
LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight
It targets the mRNA of PCSK9 (proprotein convertase subtilisin ... In the US, LEQVIO is approved for use alongside diet and statin therapy in adults with primary hyperlipidemia, including those ...
Mena FN6d
LEQVIO Strengthens Position As Leader In Cholesterol-Lowering Therapies Across Seven Major Markets Delveinsight
As the first FDA-approved siRNA therapy for LDL-C reduction ... Report " highlights the details around LEQVIO, which is a PCSK9 Inhibitor. The report provides product descriptions, patent details ...